Chembio Diagnostics to Report Second Quarter 2021 Financial Results on August 5, 2021
Chembio Diagnostics (CEMI) is set to release its second-quarter financial results on August 5, 2021, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Chembio Diagnostics (CEMI) is set to release its second-quarter financial results on August 5, 2021, after market close. A conference call for investors will follow at 4:30 p.m. ET. Interested parties can access the call via phone or online. Chembio specializes in point-of-care diagnostics for infectious diseases, leveraging its DPP technology for diverse applications globally. The company serves hospitals, clinics, and public health organizations.
Positive
- Anticipation of second-quarter financial results may indicate potential growth opportunities.
- Strong focus on point-of-care diagnostics for infectious diseases aligns with current healthcare needs.
Negative
- None.
Details
News Market Reaction – CEMI
The recorded move for CEMI in the trading session of this news was -29.00%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HAUPPAUGE, N.Y., July 22, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the second quarter of 2021 after the close of trading on Thursday, August 5, 2021.
The company’s management team will host a corresponding conference call beginning at 4:30 p.m. Eastern Time on August 5, 2021. Investors interested in listening to the conference call may do so by dialing 888-506-0062 from the US or 973-528-0011 from outside the US and providing Entry Code: 629053 or by accessing www.chembio.com/investors/calendar-of-events/. A replay of the call will be available by dialing 877-481-4010 from the US or 919-882-2331 from outside the US using passcode 41881 or by accessing www.chembio.com/investors/calendar-of-events/.
About Chembio Diagnostics
Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Coupled with Chembio’s extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at www.chembio.com.
Investor contact:
Philip Taylor
Gilmartin Group
(415) 937-5406
investor@chembio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.